SCHEMBL1666324

SCHEMBL1666324

O=C1CCCC1C(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
MCL1 Q07820 1/20 0.50
TSHR P16473 1/20 0.49
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48
NCSTN Q92542 1/20 0.48
APH1A Q96BI3 1/20 0.48
PSENEN Q9NZ42 1/20 0.48
FKBP1A P62942 4/20 0.47
FABP7 O15540 1/20 0.46
FABP5 Q01469 1/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128136 0.95 MCL1 (0.56) CYP3A4CYP2C9CYP2C19MCL1TSHR
SCHEMBL5319406 0.95 MCL1 (0.56) CYP3A4CYP2C9CYP2C19MCL1TSHR
SCHEMBL988117 0.91 TSHR (0.51) CYP3A4CYP2C9CYP2C19TSHRFKBP1A
SCHEMBL6631309 0.82 TSHR (0.47) CYP3A4CYP2C9CYP2C19TSHRFKBP1A
SCHEMBL25199049 0.80 CYP2C9 (0.45) CYP3A4CYP2C9CYP2C19MCL1TSHR
SCHEMBL18084809 0.80 SMN1; SMN2 (0.52) CYP3A4CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL761819 0.79 ALDH1A1 (0.52) CYP3A4CYP2C9CYP2C19TSHRFKBP1A
SCHEMBL19815901 0.78 HTR2C (0.46) CYP3A4CYP2C9CYP2C19TSHRFABP7
SCHEMBL13319642 0.78 FKBP1A (0.47) CYP3A4CYP2C9CYP2C19TSHRFKBP1A
SCHEMBL3709845 0.78 TSHR (0.49) TSHRFKBP1AFABP7FABP5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105521826-B A kind of Zr catalyst and its prepare chiral alpha-hydroxy-beta -one ester compound method 大连理工大学 2018-12-21 CN disclosed
US-9701684-B2 Chiral fluorinating reagents OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2017-07-11 US disclosed
CN-104230734-B Synthesis method for alpha-alkylation by visible light catalysis of secondary amine 中国科学院理化技术研究所 2016-06-29 CN disclosed
CN-105521826-A Zirconium catalyst and method for preparing chiral alpha-hydroxy-beta-keto ester compound by use of zirconium catalyst UNIV DALIAN TECH 2016-04-27 CN disclosed
US-9221819-B2 Spirocyclic compounds as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-29 US disclosed
US-9221819-B2 Spirocyclic compounds as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-29 US disclosed
US-20150284401-A1 CHIRAL FLUORINATING REAGENTS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2015-10-08 US disclosed
CN-104230734-A Synthesis method for alpha-alkylation by visible light catalysis of secondary amine CHINESE ACAD TECH INST PHYSICS 2014-12-24 CN disclosed
US-8877749-B2 Spirocyclic compounds as modulators of chemokine receptor activity Bristol-Myers Squibbs Company (US) 2014-11-04 US disclosed
US-8877749-B2 Spirocyclic compounds as modulators of chemokine receptor activity Bristol-Myers Squibbs Company (US) 2014-11-04 US disclosed
WO-2011044197-A1 SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-14 WO disclosed
US-20100330064-A1 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2010-12-30 US disclosed
CN-101928241-A 2-mercaptopentancarboxacid acid derivatives, its preparation method and contain their medicinal compositions SERVIER LAB 2010-12-29 CN disclosed
US-7332622-B2 Process for preparing optically active nitro compounds and cyano compounds KANTO KAGUKU KABUSHIKI KAISHA (JP) 2008-02-19 US disclosed
US-7332622-B2 Process for preparing optically active nitro compounds and cyano compounds KANTO KAGUKU KABUSHIKI KAISHA (JP) 2008-02-19 US disclosed
US-6642035-B2 Synthesis of B-keto esters THE SCRIPPS RESEARCH INSTITUTE 2003-11-04 US disclosed
US-20020102671-A1 Synthesis of B-keto esters SCRIPPS RESEARCH INSTITUTE, THE 2002-08-01 US disclosed
US-4695647-A RADIOACTIVE MATERIALS DRUG SCIENCE FOUNDATION (US) 1987-09-22 US disclosed
EP-0217037-A2 Stable isocyanate/epoxide prepolymers and thermoset polyurethanes produced therefrom Ashland Oil, Inc. (US) 1987-04-08 EP disclosed
US-4614786-A Stable isocyanate/epoxide prepolymers and thermoset polyurethanes produced therefrom ASHLAND OIL INC. (US) 1986-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284401-A1 CHIRAL FLUORINATING REAGENTS TIAM1, AFF2, AFF1 CYP3A4 532/4885CYP2C9 820/4885CYP2C19 752/4885
US-20100330064-A1 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them CYP2B6, CYP2A6, MC5R CYP3A4 13/4885CYP2C9 18/4885CYP2C19 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.